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Abstract
Background: The production and use of nanoparticles is growing rapidly due to the unique
physical and chemical properties associated with their nano size and large surface area. Since
nanoparticles have unique physicochemical properties, their bioactivity upon exposure to workers
or consumers is of interest. In this study, the issue of what dose metric (mass dose versus surface
area dose) is appropriate for toxicological studies has been addressed. Rats were exposed by
intratracheal instillation to various doses of ultrafine or fine TiO2. At 1, 7, or 42 days post-
exposure, inflammatory and cytotoxic potential of each particle type was compared on both a mass
dosage (mg/rat) as well as an equal surface area dosage (cm2 of particles per cm2 of alveolar
epithelium) basis.
Results:  The findings of the study show that on a mass basis the ultrafine particles caused
significantly more inflammation and were significantly more cytotoxic than the fine sized particles.
However, when doses were equalized based on surface area of particles delivered, the ultrafine
particles were only slightly more inflammogenic and cytotoxic when compared to the fine sized
particles. Lung burden data indicate that ultrafine TiO2 appears to migrate to the interstitium to a
much greater extent than fine TiO2.
Conclusion: This study suggests that surface area of particles may be a more appropriate dose
metric for pulmonary toxicity studies than mass of particles.
Background
Nanoscience and nanotechnology offer new opportuni-
ties for making superior materials for use in industrial and
health applications [1,2]. As the field of nanotechnology
vastly expands, many questions involving the effects of
nanomaterials on the environment as well as human
health have been raised which warrant investigation. The
primary problem plaguing the field of nanotechnology is
the possibility that nanoparticles can become suspended
in air during production, incorporation into consumer
products, and use or disposal of such products. Therefore,
manufactured nanoparticles can become a component of
the indoor and outdoor environments and, thus, the air
we breathe [2].
A number of toxicology studies have suggested that for
some classes of materials, biological response following
deposition in the lungs is dependent on particle surface
area [3,4]. Materials of interest typically possess character-
istics such as low solubility, which leads to extended per-
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sistence in the lungs. These materials can be produced as
ultrafine particles, which have high specific surface areas
[5]. Titanium dioxide (TiO2) is an example of a fine, low
solubility particle which was considered to exhibit rela-
tively low toxicity [6]. However, in a key study, Ferin et al.
[7] demonstrated that ultrafine TiO2  (UFTiO2) caused
more inflammation in rat lungs than exposure to the same
airborne mass concentration of fine TiO2 (FTiO2). Up
until this point in time, TiO2 often had been used as a low
solubility, low toxicity, control dust in many studies.
Therefore, this report was highly influential in highlight-
ing that a material that was low in solubility and toxicity
in the form of fine particles could be bioactive in the form
of ultrafine particles [8].
In the last decade, it has become clear from rat studies that
chronic exposure to high airborne mass concentrations of
low solubility, low toxicity particles, such as carbon black
and titanium dioxide, can lead to development of the fea-
tures characteristic of "rat lung overload" [9]. A break-
down in normal alveolar macrophage- mediated
clearance is seen in overload. This particle-induced
depression of clearance was proposed to be a consequence
of volumetric overload of the alveolar macrophages and
the resulting loss of alveolar macrophage mobility [10].
This overload phenomenon was thought to be a problem
related to particles occupying a large volume inside each
macrophage and, thus, preventing them from phagocytos-
ing additional particles and moving to the mucociliary
escalator to be cleared. This was known as the volumetric
overload hypothesis [8,10]. However, more recent studies
suggest that volumetric overload is not a complete expla-
nation for the toxicological response to ultrafine particles.
Recent evidence has suggested that surface area may drive
inflammation [11]. Exposure of rats to nanoparticles, with
a large surface area per mass, showed features of poor
clearance and inflammation at a lower lung burden, in
terms of mass and volume of particles, compared with
larger size particles with the same mineral and chemical
properties [4].
A study conducted by Tran et al. [11] compared the
inflammatory response to inhalation of two sizes of two
very different types of low solubility, low toxicity particles.
At an equal lung mass burden, the smaller particles were
more inflammatory than the larger particles. However,
when the lung burden was expressed as total particle sur-
face area delivered, the inflammatory potential of the
large and small particles was similar [11]. This supports
the hypothesis that surface area of the particle may be an
important component of toxic potential. In contrast, in
vitro studies by Monteiller et al. [9] utilized insoluble
quartz, which has a very high surface reactivity. Due to
this very high surface reactivity, quartz stimulated release
of inflammatory mediators at a much lower mass and sur-
face area dose than did low solubility, low toxicity parti-
cles. This is consistent with the high inflammatory
potential of quartz in animal models. The outcome of this
study indicates that, while surface area is important, sur-
face activity is also a critical factor to assess pulmonary
toxicity of particles. Studies supporting an important role
of particle surface area in the bioactivity of low solubility,
low toxicity particles, such as ultrafine carbon black and
ultrafine titanium dioxide, impact assessment of work-
place and environmental exposure to these nanoparticles,
since regulations are currently based on mass of airborne
particles [9].
In summary, several studies have concluded that on an
equal mass dose basis ultrafine or nano-sized particles are
uniquely more toxic than fine-sized particles of the same
composition due to a high particle surface area for the
nanoparticles [4,7-9,11]. Recently, this conclusion has
been questioned [12,13]. It is possible that these conflict-
ing results may be due to the use of highly agglomerated
UFTiO2 samples in the later two studies [12,13]. There-
fore, the aim of the present study was to readdress the
issue of the relative toxicity of UFTiO2 vs FTiO2 on a mass
dose or equivalent particle surface area delivered dose
basis using alveolar lining fluid, which our laboratory has
shown previously greatly improves nanoparticles disper-
sion [14], as the particle suspension medium. In the
present study, in vivo intratracheal exposures of rats to
ultrafine and fine titanium dioxide were conducted. Ani-
mals were given a dose of particles based on mass, and
dose was normalized to surface area of particles adminis-
tered. Particle-induced changes in several pulmonary tox-
icity parameters were compared on a mass dose and
surface area of particles administered basis to determine
which dose metric is more appropriate in nanoparticle
toxicology studies.
Results
UFTiO2  and FTiO2  suspended in acellular BALF were
administered to Fischer 344 rats via intratracheal instilla-
tion to assess pulmonary toxicity. BALF was used as the
suspension medium, because it greatly improves disper-
sion of TiO2 [14]. Figure 1 shows electron micrographs of
the ultrafine (1A) and fine (1B) particles in suspension,
indicating that the majority of ultrafine particles agglom-
erates were in the 200–300 nm range while the fine parti-
cles exceeded 1 um in diameter. The dose of particles
administered was expressed on a mass basis (mg/rat) and
was also normalized to surface area of particles adminis-
tered per alveolar epithelial surface area (cm2/cm2). The
surface areas of the respective particles were determined
by the BET gas absorption technique with values of 48.08
m2/g for UFTiO2 and 2.34 m2/g for FTiO2 [15]. This com-
parison of mass and surface area doses was conducted to
assess whether surface area of particles administered is the
more accurate dose metric that should be considered
when assessing nanoparticle pulmonary toxicity parame-Particle and Fibre Toxicology 2008, 5:17 http://www.particleandfibretoxicology.com/content/5/1/17
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ters. Pulmonary response parameters measured included,
indicators of pulmonary inflammation (PMN number or
inflammatory mediators, such as TNF-α, MIP-2, and IL-
1β), markers of lung injury (LDH activity or albumin lev-
els) and markers of macrophage activity (zymosan-stimu-
lated chemiluminescence and NO-dependent
chemiluminescence).
Comparison of pulmonary toxicity of UFTiO2 and FTiO2
On a mass dose basis, UFTiO2 and FTiO2 both produced a
dose-dependent increase in PMN harvested by BAL (Fig-
ure 2). All doses of UFTiO2 caused a significant increase in
PMN over control at all post-exposure time periods. For
FTiO2, the medium and high doses caused a significant
increase in PMN number over control at all post-exposure
days. However, it took a significantly larger mass dose of
FTiO2 to obtain the same inflammogenic response as the
UFTiO2 particles (Figure 2). When comparing this inflam-
mogenic response for UFTiO2 exposure to FTiO2 exposure,
on a mass dose basis (for example the PMN response to
10.7 mg/rat FTiO2 vs 0.26 mg/rat UFTiO2 from figure 2),
UFTiO2 was shown to be 41 times more potent than the
FTiO2 at all exposure times (Table 1). However, when
dose of particles was normalized to surface area of parti-
Electron micrographs of titanium dioxide particles suspended in BALF Figure 1
Electron micrographs of titanium dioxide particles suspended in BALF. A transmission electron micrograph of 
UFTiO2 suspended in BALF (A). Magnification of 60,000 × (note 500 nm scale bar). A scanning electron micrograph of FTiO2 
suspended in BALF (B). Magnification of 20,000 × (note 1 um scale bar).Particle and Fibre Toxicology 2008, 5:17 http://www.particleandfibretoxicology.com/content/5/1/17
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cles administered the difference in inflammogenic
responses, assessed by PMN number, of the two particle
types was much less (Figure 3). Indeed, a linear regression
curve analysis with a 95% confidence interval showed that
there was no significant difference between the dose-
response curves for UFTiO2 and FTiO2 when dose was
expressed as total particle surface area delivered (Figure
3). In fact, when dose was normalized to surface area of
particles administered, the inflammogenic response elic-
ited by UFTiO2 was only 2-fold greater than the FTiO2
response at 1 day post-exposure, 1.3-fold greater at 7 days
post-exposure and 1.6-fold greater at 42 days post-expo-
sure (Table 1).
Lactate dehydrogenase (LDH) activity was measured to
assess cellular cytotoxicity after TiO2 exposures. As with
PMN, both UFTiO2 and FTiO2 caused a dose dependent
increase in LDH activity in BALF. For LDH activity, on a
mass dose basis, a significantly greater mass dose of FTiO2
was required at all post-exposure time points to obtain the
same responses as seen with UFTiO2 exposure (Figure 4).
For LDH activity, on a mass dose basis, UFTiO2 exposure
was shown to be approximately 30–41 times more potent
at all post-exposure time points than FTiO2 exposure
(Table 1). However, when dose of particles was normal-
ized to surface area of particles administered the differ-
ence in LDH activity of the two particle types was much
less (Figure 5). Indeed, a linear regression curve analysis
with a 95% confidence interval showed that there was no
significant difference between the dose-response curves
for UFTiO2 and FTiO2 when dose was expressed as total
particle surface area delivered (Figure 5). In fact, when
dose was normalized to surface area of particles adminis-
tered, the UFTiO2 exposure produced LDH activity levels
that were at most only 1.8-fold greater than the FTiO2
exposure at all post-exposure time points analyzed (Table
1).
Table 1: Potency difference between UFTiO2 and FTiO2 when analyzed on a mass vs. surface area basis.
Parameter Dose Metric 1 Day 7 Days 42 Days
PMN (106)
Mass 41 41 41
Surface Area 2 1.3 1.6
LDH (U/l)
Mass 41 30 41
Surface Area 1.2 1.2 1.8
Albumin
Mass 82 41 41
Surface Area 3 1.4 2
TNF-α (pg/ml)
Mass 41 41 41
Surface Area 1.2 1.4 1.5
MIP-2 (pg/ml)
Mass 41 41 82
Surface Area 1.2 1.1 1.1
IL-1β (pg/ml)
Mass 82 82 82
Surface Area 1.6 1.8 1.4
Zym. Stim. Chemi.
Mass 82 82 82
Surface Area 1.75 1.8 3
NO Dep. Chemi.
Mass 41 82 82
Surface Area 1.5 7 8
Comparison of UFTiO2 and FTiO2 potency differences. The data were analyzed to show the potency difference between UFTiO2 and FTiO2 on a 
mass basis as well as the fold increase in pulmonary toxicity response on a surface area basis. All post-exposure time points were analyzed and are 
reported in the table. On a mass basis, the UFTiO2 has much greater potency than FTiO2, but when dose is normalized to total particle surface area 
administered the fold increase in response between the UFTiO2 and FTiO2 is greatly reduced.Particle and Fibre Toxicology 2008, 5:17 http://www.particleandfibretoxicology.com/content/5/1/17
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A comparison of inflammation elicited in animals receiving various mass doses of UFTiO2 and FTiO2 suspended in BALF Figure 2
A comparison of inflammation elicited in animals receiving various mass doses of UFTiO2 and FTiO2 sus-
pended in BALF. A comparison of inflammation elicited in animals receiving various mass doses of UFTiO2 and FTiO2 sus-
pended in BALF at 1 day (Panel A), 7 days (Panel B), and 42 days (Panel C) post-exposure. Rats were exposed to various mass 
doses of UFTiO2 and FTiO2 by intratracheal instillation. Animals were euthanized at 1 day, 7 days, and 42 days post-exposure 
and bronchoalveolar lavage was performed. Inflammation was assessed by BAL PMN counts. Values are increased PMN 
number above the BALF control and are given as means ± SE of 8 experiments. Control PMN values were 1.37 ± 0.098 × 106, 
0.78 ± 0.074 × 106, and 0.88 ± 0.095 × 106 cells/rat for 1, 7 and 42 days, respectively. Linear regression analysis with a 95% con-
fidence interval reveals that on a mass dose basis UFTiO2 causes significantly more inflammation than FTiO2 at all post-expo-
sure time points. * indicates a significant increase from control (p < 0.05; ANOVA).
A comparison of inflammation elicited in animals receiving doses of UFTiO2 and FTiO2 normalized to surface area of particles  administered per surface area of alveolar epithelium Figure 3
A comparison of inflammation elicited in animals receiving doses of UFTiO2 and FTiO2 normalized to surface 
area of particles administered per surface area of alveolar epithelium. A comparison of inflammation elicited in ani-
mals receiving doses (0.0313, 0.0625 and 0.125 cm2/cm2) of UFTiO2 and FTiO2 normalized to surface area of particles adminis-
tered per surface area of alveolar epithelium at 1 day (Panel A), 7 days (Panel B), and 42 days (Panel C) post-exposure. Particles 
were suspended in BALF. Rats were exposed to various doses of UFTiO2 and FTiO2 by intratracheal instillation. Animals were 
euthanized at 1 day, 7 days, and 42 days post-exposure and bronchoalveolar lavage was performed. Inflammation was assessed 
by BAL PMN counts. Values are increased PMN number above the BALF control and are given as means ± SE of 8 experi-
ments. Control PMN values were 1.37 ± 0.098 × 106, 0.78 ± 0.074 × 106, and 0.88 ± 0.095 × 106 cells/rat for 1, 7 and 42 days, 
respectively. Linear regression analysis with a 95% confidence interval reveals that, when dose is normalized to surface area of 
particles administered, dose responses curves assessing inflammation caused by UFTiO2 and FTiO2 exposure are not signifi-
cantly different. On a dose normalized to surface area, UFTiO2 elicits at most a 2 fold increase in inflammation when compared 
to FTiO2 at all post-exposure times.Particle and Fibre Toxicology 2008, 5:17 http://www.particleandfibretoxicology.com/content/5/1/17
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A comparison of cellular cytotoxicity elicited in animals receiving various mass doses of UFTiO2 and FTiO2 suspended in BALF Figure 4
A comparison of cellular cytotoxicity elicited in animals receiving various mass doses of UFTiO2 and FTiO2 sus-
pended in BALF. A comparison of cellular cytotoxicity elicited in animals receiving various mass doses of UFTiO2 and FTiO2 
suspended in BALF at 1 day (Panel A), 7 days (Panel B), and 42 days (Panel C) post-exposure. Rats were exposed to various 
mass doses of UFTiO2 and FTiO2 by intratracheal instillation. Animals were euthanized at 1 day, 7 days, and 42 days post-expo-
sure and bronchoalveolar lavage was performed. Cytotoxicity was assessed by measuring LDH activity. Values are increase in 
LDH activity above the BALF control and are given as means ± SE of 8 experiments. Control values of LDH activity were 
46.375 ± 2.24, 39.5 ± 1.35, and 37.25 ± 2.63 U/l for 1, 7 and 42 days, respectively. Linear regression analysis with a 95% confi-
dence interval reveals that on a mass dose basis UFTiO2 causes significantly more LDH activity than FTiO2 at all post-exposure 
time points. * indicates a significant increase from control (p < 0.05; ANOVA).
A comparison of cytotoxicity elicited in animals receiving doses of UFTiO2 and FTiO2 normalized to surface area of particle  administered per surface area of alveolar epithelium Figure 5
A comparison of cytotoxicity elicited in animals receiving doses of UFTiO2 and FTiO2 normalized to surface 
area of particle administered per surface area of alveolar epithelium. A comparison of cytotoxicity elicited in animals 
receiving doses (0.0313, 0.0625 and 0.125 cm2/cm2) of UFTiO2 and FTiO2 normalized to surface area of particles administered 
per surface area of alveolar epithelium at 1 day (Panel A), 7 days (Panel B), and 42 days (Panel C) post-exposure. Animals were 
exposed to various doses of UFTiO2 and FTiO2 by intratracheal instillation. Animals were euthanized at 1 day, 7 days, and 42 
days post-exposure and bronchoalveolar lavage was performed. Cytotoxicity was assessed by measuring LDH activity. Values 
are increase in LDH activity above the BALF control and are given as means ± SE of 8 experiments. Control values of LDH 
activity were 46.375 ± 2.24, 39.5 ± 1.35, and 37.25 ± 2.63 U/l for 1, 7 and 42 days, respectively. Linear regression analysis with 
95% confidence internal reveals that, when dose is normalized to surface area of particles administered, responses to UFTiO2 
and FTiO2 are not significantly different.Particle and Fibre Toxicology 2008, 5:17 http://www.particleandfibretoxicology.com/content/5/1/17
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Albumin levels in BALF were analyzed to assess air/blood
barrier injury after TiO2  exposures. Both UFTiO2  and
FTiO2 caused a dose dependent increase in albumin levels.
For albumin levels, on a mass dose basis, a significantly
greater mass dose of FTiO2 was required at all post-expo-
sure time points, to obtain the same responses as seen
with UFTiO2 exposure (Figure 6). In fact, for albumin lev-
els, UFTiO2 exposure was shown to be approximately 82
times more potent than FTiO2 at 1 day post-exposure and
41 times more potent at 7 and 42 days post-exposure
when mass was the dose metric (Table 1). However, when
dose of particles was normalized to surface area of parti-
cles administered the difference in albumin levels of the
two particle types was much less (Figure 7). Indeed, a lin-
ear regression curve analysis with a 95% confidence inter-
val showed that there was no significant difference
between the dose-response curves for UFTiO2 and FTiO2
when dose was expressed as total particle surface area
delivered (Figure 7). When dose was normalized to sur-
face area of particles administered, the UFTiO2 exposure
produced albumin levels that were at most only 3 fold
greater than the FTiO2 exposure at all post-exposure time
points analyzed (Table 1).
IL-1β, TNF-α, and MIP-2 levels were also measured in
response to various mass doses of UFTiO2 and FTiO2 at all
post-exposure time points (data similar to Figures 2, 4 and
6 not shown). The highest dose of UFTiO2 caused a signif-
icant increase in TNF-α, IL-1β and MIP-2 mediator levels
over control values at all post-exposure time points (Table
2). The high dose of FTiO2 caused a significant increase in
MIP-2 and TNF-α levels at all post-exposure time points
and caused a significant increase in IL-1β cytokine levels
at 7 days and 42 days post-exposure (Table 2). For all
three mediators, a significantly greater mass dose of FTiO2
was required to obtain the comparable levels in the BAL
fluid as elicited by UFTiO2 exposure (Table 1). For TNF-α
cytokine levels, on a mass dose basis, UFTiO2 was shown
to be 41 times more potent than FTiO2 at all post-expo-
sure time points (Table 1). However, when dose was nor-
malized to surface area of particles administered, TNF-α
cytokine levels produced by UFTiO2 exposure were at
most only 1.5-fold greater than FTiO2 levels. For MIP-2
levels, on a mass dose basis, UFTiO2 was shown to be 41
times more potent than FTiO2 at 1 and 7 days post-expo-
sure and 82 times more potent at 42 days post-exposure
(Table 1). However, when dose was normalized to surface
area of particles administered, MIP-2 levels produced by
UFTiO2 exposure were at most only 1.2-fold greater than
FTiO2 levels (Table 1). In regards to IL-1β cytokine levels,
on a mass dose basis, UFTiO2 was shown to be 82 times
more potent than FTiO2 at all post-exposure time points
(Table 1). However, when dose was normalized to surface
area of particles administered, IL-1β cytokine levels pro-
duced by UFTiO2 exposure were at most only 1.8-fold
greater than FTiO2 levels (Table 1). Dose response curves
A comparison of cellular damage elicited in animals receiving various mass doses of UFTiO2 and FTiO2 suspended in BALF Figure 6
A comparison of cellular damage elicited in animals receiving various mass doses of UFTiO2 and FTiO2 sus-
pended in BALF. A comparison of cellular damage elicited in animals receiving various mass doses of UFTiO2 and FTiO2 sus-
pended in BALF at 1 day (Panel A), 7 days (Panel B), and 42 days (panel C) post-exposure. Rats were exposed to various mass 
doses of UFTiO2 and FTiO2 by intratracheal instillation. Animals were euthanized at 1 day, 7 days, and 42 days post-exposure 
and bronchoalveolar lavage was performed. Cellular injury was assessed by measuring albumin levels. Control values of albumin 
levels were 0.073 ± 0.033, 0.084 ± 0.003, 0.098 ± 0.007 mg/ml for 1, 7, and 42 days, respectively. Values are increase in albumin 
levels above the BALF control and are given as means ± SE of 8 experiments. * indicates a significant increase from control (p 
< 0.05; ANOVA).Particle and Fibre Toxicology 2008, 5:17 http://www.particleandfibretoxicology.com/content/5/1/17
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assessing TNF-α, IL-1β, and MIP-2 levels based on surface
area of particles administered between UFTiO2 and FTiO2
exposure were assessed using a linear regression curve
analysis with a 95% confidence interval (data similar to
Figures 3, 5 and 7 not shown). This analysis showed there
was no significant difference in the potency of UFTiO2 vs
FTiO2 for any of the mediators between the two curves at
any post-exposure time point.
Alveolar macrophage zymosan-stimulated and NO-
dependent chemiluminescence were measured to assess
reactive oxygen species production after UFTiO2  and
FTiO2 exposures. On a mass dose basis, UFTiO2 and FTiO2
both caused dose-dependent increases in zymosan-stimu-
lated and NO dependent chemiluminescence (data anal-
ogous to Figures 2, 4 and 6 not shown). The responses to
the high dose are shown in Table 2. A significantly greater
mass dose of FTiO2 was required to produce comparable
chemiluminescence levels as elicited by UFTiO2 exposure.
The highest doses of UFTiO2 caused a significant increase
in zymosan and NO-dependent chemiluminescence lev-
els over control at all post-exposure time points (Table 2).
The high dose of FTiO2 caused a significant increase over
control in zymosan-stimulated chemiluminescence at 1
and 7 days post-exposure and in NO-dependent chemilu-
minecence only at 1 day post-exposure (Table 2).
On a mass dose basis, in regards to zymosan-stimulated
chemiluminescence levels, UFTiO2 was shown to be 82
times more potent than FTiO2 at all post-exposure time
points (Table 1). However, when dose was normalized to
surface area of particles administered, UFTiO2 zymosan-
stimulated chemiluminecence levels were at most only 3
fold higher than FTiO2 zymosan-stimulated chemilumi-
necence levels (Table 1). When the surface area zymosan-
stimulated chemiluminescence dose response curves were
analyzed using a linear regression curve with a 95% confi-
dence interval (data not shown), there was no significant
difference between the UFTiO2 and FTiO2 dose response
curves at 1 day or 7 days post-exposure.
On a mass dose basis, in regards to NO-dependent chemi-
luminescence levels, UFTiO2 was 41 times more potent
than FTiO2 at 1 day post-exposure and was 82 times more
potent at 7 and 42 days post-exposure. However, when
dose was normalized to surface area of particles adminis-
tered, UFTiO2 NO-dependent chemiluminescence levels
were only 1.5-fold greater than FTiO2 at 1 day post-expo-
sure but were 8-fold greater at 42 days post-exposure
(Table 1). When the surface area NO-dependent chemilu-
minescence dose response curves were analyzed using a
linear regression curve with a 95% confidence interval
(data not shown), there was no significant difference
A comparison of cellular damage elicited in animals receiving doses of UFTiO2 and FTiO2 normalized to surface area of particle  administered per surface area of alveolar epithelium Figure 7
A comparison of cellular damage elicited in animals receiving doses of UFTiO2 and FTiO2 normalized to sur-
face area of particle administered per surface area of alveolar epithelium. A comparison of cellular damage elicited 
in animals receiving doses (0.0313, 0.0625 and 0.125 cm2/cm2) of UFTiO2 and FTiO2 normalized to surface area of particles 
administered per surface area of alveolar epithelium at 1 day (Panel A), 7 days (Panel B), and 42 days (Panel C) post-exposure. 
Rats were exposed to various mass doses of UFTiO2 and FTiO2 by intratracheal instillation. Animals were euthanized at 1 day, 
7 days, and 42 days post-exposure and bronchoalveolar lavage was performed. Cellular injury was assessed by measuring albu-
min levels. Control values of albumin levels were 0.073 ± 0.033, 0.084 ± 0.003, 0.098 ± 0.007 mg/ml for 1, 7, and 42 days, 
respectively. Values are increase in albumin levels above the BALF control and are given as means ± SE of 8 experiments. Lin-
ear regression analysis with a 95% confidence interval reveals that, when dose is normalized to surface area of particles admin-
istered, responses to UFTiO2 and FTiO2 are not significantly differently.Particle and Fibre Toxicology 2008, 5:17 http://www.particleandfibretoxicology.com/content/5/1/17
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between the UFTiO2 and FTiO2 dose response curves at 1
day post-exposure.
Pulmonary fibrosis
At 42 days post-exposure, lungs were evaluated for pul-
monary fibrosis by histological examination of lung tissue
stained with Masson's trichrome. No excess fibrotic tissue
was noted in lungs exposed to either UFTiO2 or FTiO2
(micrographs not shown).
Comparison of lung burden data from TiO2 metal analysis
Rats were exposed to the medium dose of UFTiO2 or
FTiO2 (0.52 mg/rat or 10.7 mg/rat, respectively). This
mass exposure resulted in the same particle surface area
delivered to the lung (0.06 cm2 particles/cm2 alveolar epi-
thelial surface). The amount of UFTiO2 or FTiO2 in the
lung was determined at 7 day and 42 day post-exposure.
The metal analysis results indicate that the amount of
UFTiO2 remaining in the lung decreased by 51% from the
7 day to the 42 day post-exposure time period, while the
lung burden of FTiO2 decreased by 12% (Table 3).
Comparison of lymph node burden data from TiO2 metal 
analysis
To determine if the decline in lung burden was due to
migration of particles to the lymph nodes, the amount of
TiO2 present in the tracheo-bronchial (TBL) and thymic
lymph nodes (TLN) was assessed at days 7 and 42 post-
Table 2: Effect of Exposure to UFTiO2 vs. FTiO2 (High Dose) on Pulmonary Responses.
Parameter Group 1 day 7 days 42 days
PMN (106) Control 1.4 ± 0.1 0.78 ± 0.07 0.88 ± 0.10
UFTiO2 high 23.8 ± 1* 25.5 ± 3* 18.3 ± 1*
FTiO2 high 15.6 ± 0.9* 19.8 ± 0.7* 10.8 ± 0.4*
LDH (U/l) Control 46.3 ± 2 39.5 ± 1.35 37.3 ± 2
UFTiO2 high 337.4 ± 3* 323.5 ± 3* 239.9 ± 5*
FTiO2 high 307.6 ± 5* 288.1 ± 5* 175.6 ± 4*
Albumin Control 0.07 ± 0.03 0.08 ± 0.003 0.09 ± 0.007
UFTiO2 high 0.38 ± 0.04* 0.51 ± 0.02* 0.40 ± 0.01*
FTiO2 high 0.21 ± 0.055* 0.40 ± 0.01* 0.30 ± 0.01*
TNF-α (pg/ml) Control 25.7 ± 0.6 23.1 ± 0.7 25.86 ± 0.8
UFTiO2 high 67.4 ± 2.2* 73.5 ± 1.5* 88.5 ± 4.4*
FTiO2 high 60.7 ± 1.7* 58.5 ± 2.8* 55.4 ± 1.3*
MIP-2 (pg/ml) Control 517.9 ± 12 601.8 ± 26 643.6 ± 7
UFTiO2 high 802.9 ± 28* 886.9 ± 21* 893.5 ± 26*
FTiO2 high 695.6 ± 15* 847.1 ± 43* 852.1 ± 22*
IL-1β (pg/ml) Control 75.9 ± 6 82.2 ± 6 91.9 ± 8
UFTiO2 high 167.5 ± 13* 230.4 ± 14* 273.6 ± 14*
FTiO2 high 119.9 ± 13 131.5 ± 11* 180.3 ± 14*
Zym. Stim. Chemi. Control 0.53 ± .08 0.50 ± .05 0.51 ± .05
UFTiO2 high 4.4 ± .51* 4.4 ± .47* 4.2 ± .48*
FTiO2 high 2.6 ± .26* 2.8 ± .35* 1.4 ± .27
NO Dep. Chemi. Control 4.3 ± .06 0.45 ± .11 0.39 ± .08
UFTiO2 high 3.3 ± .11* 2.2 ± .27* 1.0 ± .12*
FTiO2 high 2.6 ± .20* 0.28 ± .04 0.230 ± .04
Comparison of pulmonary toxicity parameters measured in control animals and for animals receiving the high doses (1.04 and 21.41 mg/rat) of 
UFTiO2 and FTiO2 at all post-exposure time points. * denotes that the change from control is statistically significant (p < 0.05) using ANOVA.
Table 3: Decline in lung burden from 7 to 42 days post – 
exposure
Particle Percent decline
UFTiO2 51 ± 4%
FTiO2 12 ± 1%
Values are for medium dose exposures (0.52 mg/rat vs 10.7 mg/rat for 
UFTiO2 and FTiO2, respectively, i.e., a surface area dose of 0.06 cm2 
particles/cm2 alveolar epithelial surface). Values are means ± SE of at 
least 4 experiments.Particle and Fibre Toxicology 2008, 5:17 http://www.particleandfibretoxicology.com/content/5/1/17
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exposure. The results indicate that lymph node burden for
UFTiO2 from 7 to 42 days post-exposure increased by
246%, while a 134% increase was observed for FTiO2
(Table 4). Therefore, although relative migration of
UFTiO2 to the lymph nodes exceeded that for FTiO2, this
difference could not account for the much lower lung
clearance of FTiO2 relative to UFTiO2 (Table 3).
Comparison of lavaged lung burden data from TiO2 metal 
analysis
Lung burden of TiO2 was measured in both lavaged and
unlavaged lungs at 7 and 42 days post-exposure. The
amount of TiO2 present in the lavaged lung is the non-lav-
agable fraction, i.e., the fraction not phagocytized by lav-
agable alveolar macrophages or present as free particles in
the airspaces. The non-lavagable fraction would be
expected to increase if particles migrated to the intersti-
tium. The non-lavagable UFTiO2 or FTiO2 present in the
lavaged lung increased from 7 to 42 days post-exposure
(Table 5). However, there was a striking difference
between the lavagable vs non-lavagable component of
UFTiO2 compared to FTiO2. With UFTiO2, the majority of
the particles were non-lavagable, suggesting migration to
the interstitium. In contrast, the majority of FTiO2 was
found in lavagable alveolar macrophages at both 7 and 42
days post-exposure.
Discussion
Fine TiO2 particles as well as other low-solubility, low-tox-
icity particles have long been of interest in particle toxicol-
ogy. Historically, fine TiO2  particles were utilized as
negative controls in numerous pulmonary toxicity stud-
ies. However, the current study shows that FTiO2 at rela-
tively high mass lung burdens can induce pulmonary
inflammation and damage, which are sustained through
42 days post-exposure. Using a mass dose metric, UFTiO2
was significantly more potent (at least 41 fold) than FTiO2
in causing sustained lung damage and inflammation.
When exposure dose was normalized to equivalent sur-
face area of particles delivered, no significant difference in
potency between UFTiO2 and FTiO2 was observed. These
findings help support the hypothesis that surface area of
particles administered may be the more appropriate dose
metric for nanoparticle pulmonary toxicity studies. This
conclusion, although not novel, has been recently dis-
puted [12,13].
Two similar studies were conducted by Warheit et al.
[12,13] to assess the lung toxicity of intratracheally
instilled nano-sized and fine-sized TiO2. In both studies,
they instilled fine and ultrafine TiO2 suspended in PBS
into rats (1 or 5 mg/kg) and compared measured pulmo-
nary parameters to animals instilled with crystalline silica
(used as a positive control). They monitored inflamma-
tion as PMN influx and cytotoxicity as LDH activity at 1
day, 1 week, 1 month and 3 months post-exposure in
both studies. Warheit et al. [12,13] concluded that expo-
sures to nanosized TiO2 had no significant long term
adverse pulmonary effects. They also reported similar
acute levels of inflammation and cytotoxicity for both
nano-sized and fine-sized TiO2, with only the highest
dose (5 mg/kg) at 1 day post-exposure, causing a signifi-
cant increase in inflammation for both nano- and fine-
sized TiO2 exposures. Warheit and colleagues argued that
the transient, reversible inflammation seen at 1 day post-
exposure with both nano-sized and fine-sized TiO2 was
due primarily to the method of exposure (intratracheal
instillation) rather than the effects of the nano-sized par-
ticles in the lung. The inflammation shown at 1 day post-
exposure in the Warheit et al. [12,13] studies quickly
resolved to control levels by 1 week post-exposure.
In the first study, Warheit et al. [12] concluded that their
results "run counter to the postulation that surface area is
a major factor associated with the pulmonary toxicity of
nanoscale particle-types". They argued that their study
was instrumental in demonstrating that the fact that nan-
oparticles have larger surface areas does not necessarily
indicate that they produce increased pulmonary inflam-
mation and cytotoxicity when compared to fine-sized par-
ticles of similar composition. Warheit et al. [13], using
very similar data to the Warheit et al. [12] study, expanded
on the conclusions from the initial study. They again con-
cluded that the fact that nanoparticles have larger surface
areas does not necessarily indicate that they produce
increased pulmonary inflammation and cytotoxicity
Table 4: Increase in lymph node burden from 7 to 42 days post-
exposure
Particle Percent increase
UFTiO2 246 ± 118%
FTiO2 134 ± 2%
Values are for medium dose exposures (0.52 mg/rat vs 10.7 mg/rat for 
UFTiO2 and FTiO2, respectively, i.e., a surface area dose of 0.06 cm2 
particles/cm2 alveolar epithelial surface). Values are means ± SE of at 
least 4 experiments.
Table 5: Percent lavagable vs non-lavagable TiO2 in the lung
Particle 7 Days post 42 Days post
UFTiO2 19% lavagable 0% lavagable
81% non-lavagable 100% non-lavagable
FTiO2 91% lavagable 84% lavagable
9% non-lavagable 16% non- lavagable
Values are for medium dose exposures (0.52 mg/rat vs 10.7 mg/rat for 
UFTiO2 and FTiO2, respectively, i.e., a surface area dose of 0.06 cm2 
particles/cm2 alveolar epithelial surface).Particle and Fibre Toxicology 2008, 5:17 http://www.particleandfibretoxicology.com/content/5/1/17
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when compared to fine-sized particles of similar compo-
sition.
The findings of the current study disagree with the find-
ings of Warheit et al. [12,13]. The results of the current
study indicate that surface area of the nanoparticles does
in fact play a role in pulmonary toxicity, and that low
mass burdens (as low as 0.26 mg/rat) of UFTiO2 can cause
persistent lung damage and inflammation over a 42 day
post-exposure study period. The results of the current
study support the fact that on a mass dose basis nano-
sized particles are more toxic than fine-sized particle of
the same composition. However, when dose is normal-
ized to surface area of particles administered, the differ-
ence in toxicity responses between UFTiO2 and FTiO2 for
all pulmonary parameters measured becomes substan-
tially less. This, therefore, indicates that surface area of
particles is a critical driver of toxicity and may be an
appropriate dose metric for pulmonary toxicity studies.
The discrepancies between the two studies are believed to
be due to the fact that Warheit et al. [12,13] reports
extreme agglomeration of the PBS-suspended nano-sized
TiO2  utilized in their studies. In addition, significant
agglomeration was also reported for the suspension of
fine TiO2. This agglomeration issue leads to an over-esti-
mation of delivered surface area of the particles. Indeed,
their dynamic light scattering data indicate that once sus-
pended in PBS both ultrafine and fine TiO2 had agglomer-
ated particle sizes of > 2 μm. One would argue that since
delivered particle size was equivalent, toxicity would not
be expected to differ. In the present study, efforts were
made to substantially improve the dispersion of UFTiO2
and FTIO2  by using rat bronchoalveolar lavage fluid
(BALF) as the suspension medium. Results from our lab-
oratory indicate that dispersion was vastly improved for
both UFTiO2 and FTiO2 in BALF compared to PBS [14].
Our laboratory has reported that the diameter determined
by dynamic light scattering of UFTiO2 suspended in a
BALF model medium was 204 nm [16]. Therefore, in the
present study, a potency difference between UFTiO2 and
FTiO2 (on a mass basis) was observed because the physical
surface areas of the UF vs F structures were different.
A recent study by Duffin et al. [17] further supports the
conclusions of the current study. They investigated the
relationship between inflammation, as indicated by neu-
trophil content of the bronchoalveolar lavage of rats 18–
24 hours after particle instillation, and particle size. Rats
were instilled with ultrafine and fine-sized carbon black
or titanium dioxide and then assessed for PMN influx into
the lung. Duffin et al. [17] reported that the extent of
inflammation was a function not of mass dose instilled
but of the surface area of particles instilled. Likewise, the
findings of the current study support the conclusion that
inflammatory potential of TiO2 is a function of surface
area of the particles administered.
Secondly, studies by Warheit et al. [12,13] report that
UFTiO2 at lung burdens of 1–5 mg/kg did not cause per-
sistent lung damage and inflammation. In contrast, data
from the present study indicate that lung burdens as low
as 1 mg/kg UFTiO2 caused significant lung damage and
inflammation which persisted through 42 days post-expo-
sure. In the present study, efforts were made to improve
dispersion of UFTiO2 by using BALF as the suspension
medium, as reported previously [14]. Shvedova et al. [18]
reported that improved dispersion of ultrafine carbon
black (UFCB) particles in BALF increased the inflamma-
tory and damage potency compared to UFCB suspended
in PBS; i.e., intratracheal instillation of a 30 fold greater
mass of poorly dispersed UFCB suspended in PBS was
required to attain the same level of pulmonary damage
(LDH activity) and inflammation (PMN level) as well dis-
persed UFCB suspended in BALF in a rat model. There-
fore, poor dispersion of UFTiO2 in PBS (diameters of over
2  μm determined by dynamic light scattering) may
account for the low biological activity previously reported
by Warheit et al. [12,13].
Warheit et al. [13] suggested that particle characteristics,
such as surface reactivity, crystal structure, surface pH, sur-
face coating, shape, etc., may play important roles in the
pulmonary toxicity of nanoparticles. They have demon-
strated that UFTiO2 in the uncoated, 80/20 anatase/rutile
form exhibited greater surface activity than alumina-
coated rutile as judged by ability to deplete vitamin C in
an acellular assay. In addition, Sayes et al. [19] demon-
strated that 80/20 anatase/rutile generated 6 fold more
reactive species (measured as acellular luminol-enhanced
chemiluminescence) than rutile after UV irradiation. They
argued that this increased surface reactivity resulted in
greater in vitro cytotoxicity for the anatase form of UFTiO2.
In the present study, the UFTiO2 used was 80/20 anatase/
rutile, while the FTiO2 was the rutile crystal form. How-
ever, the particle samples were not irradiated with UV
light in this study. In the absence of UV irradiation, Sayes
et al. [19] reported the UFTiO2 in the 80/20 anatase/rutile
form generated only twice the reactive species as ultrafine
rutile. Such as small difference in surface reactivity can not
account for the 40 fold greater potency of ultrafine vs. fine
TiO2 on an equal mass basis reported in the present study.
However, a 2 fold difference in surface activity may
explain why normalizing dose to equivalent particle sur-
face area delivered did not result in identical potency for
the ultrafine and fine particle samples. Recent results indi-
cate that the shape of nanoparticles can affect toxic poten-
tial. Porter et al. [20] demonstrated that TiO2 nanowires
exhibited greater toxicity in vitro and greater inflammatory
potential in vivo than TiO2 nanospheres of the same crystalParticle and Fibre Toxicology 2008, 5:17 http://www.particleandfibretoxicology.com/content/5/1/17
Page 12 of 15
(page number not for citation purposes)
structure and diameter. Therefore, although the present
study concentrated on the role of particle surface area in
nanoparticle toxicity, results do not discount the impor-
tance of other particle characteristics in nanoparticle tox-
icity.
Results of lung burden studies suggest that although a
large portion of FTiO2 appears to have been engulfed by
lavagable alveolar macrophages (Table 5) clearance of
FTiO2 was relatively low, 12% from 7 to 42 days post-
exposure (Table 3). One, thus, could conclude that the
lungs were in overload at this FTiO2 burden (10.7 mg/rat).
As proposed by Morrow [10], when alveolar macrophages
have engulfed a large volume of particles, the phagocytes
become immobile and clearance fails. In contrast, macro-
phage clearance apparently is relatively robust after expo-
sure to 0.52 mg/rat UFTiO2; i.e., 51% decline in lung
burden is observed from 7 to 42 days post-exposure
(Table 3). This clearance is only partially due to migration
of UFTiO2 to the lymph nodes (Table 4). In addition,
migration of UFTiO2 into the alveolar walls is far more
substantial than that for FTiO2 (Table 5). A high rate of
interstitilization of UFTiO2 vs FTiO2 has been reported
previously [21].
Conclusion
In summary, exposure of rats by intracheal instillation to
a well-dispersed suspension of UFTiO2  caused dose
dependent pulmonary damage and inflammation, which
persisted 42 days post-exposure. On a mass dose basis,
UFTiO2 was at least 41 fold more potent than FTiO2.
When exposure dose was normalized to surface area of
particles delivered, this potency difference was no longer
significant. Burden data indicate that UFTiO2 migrates to
the interstitium to a far greater extent than FTiO2. Results
support the use of particle surface area as a dose metric for
evaluation of pulmonary response to particles.
Methods
Experimental design
Recently, the hypothesis that nanoparticles exhibit unique
bioactivity due to their large surface area per mass has
been questioned [12,13]. The aim of the present study was
to readdress the issue of the relative toxicity of UFTiO2 vs
FTiO2 on a mass dose or equivalent particle surface area
delivered dose basis. In this study, particle dispersion was
substantially improved by suspension of particles in
diluted alveolar lining fluid obtained by bronchoalveolar
lavage of naïve rats as described previously [14]. Rats were
exposed to various mass concentrations of UFTiO2 vs
FTiO2 by intratracheal instillation. Mass doses of UFTiO2
(0.26, 0.52 and 1.04 mg/rat) and FTiO2 (5.35, 10.7 and
21.41 mg/rat) were chosen to result in equivalent total
particle surface area delivered doses (0.0313, 0.0625 and
0.125 cm2 of particles administered per cm2 of alveolar
epithelial surface) for UFTiO2 and FTiO2. Rats were sacri-
ficed at 1 day, 7 days, and 42 days post-exposure, and
markers of inflammation (PMN number or inflammatory
mediator levels in BAL samples), lung injury (LDH activ-
ity or albumin levels in BAL samples), and macrophage
activity (zymosan-stimulated or NO-dependent chemilu-
minescence) were monitored. The magnitude of pulmo-
nary responses to exposure to UFTiO2 vs FTiO2 was then
compared on a mass dose and an equivalent surface area
of particles administered dose basis to evaluate the role of
particle surface area in the pulmonary response.
Animals for in vivo exposures
The rats used for the in vivo experiments were male Fischer
CDF (F344/DuCrl) rats weighing 200–300 g (~10 weeks
old at arrival) obtained from Charles River (Raleigh, NC).
The animals were housed in an AAALAC-accredited; spe-
cific pathogen-free, environmentally controlled facility.
The animals were monitored to be free of endogenous
viral pathogens, parasites, mycoplasms, Helicobacter and
CAR Bacillus. Animals were housed in ventilated cages
which were provided HEPA-filtered air, with Alpha-Dri
virgin cellulose chips and hardwood Beta-chips used as
bedding. The rats were maintained on a Teklad 2918 diet
and tap water, both of which were provided ad libitum.
Bronchoalveolar fluid collection for particle suspension 
media
Rats were euthanized with an i.p. injection of sodium
pentobarbital (>100 mg/kg body weight) and exsanguin-
ated by cutting the descending aorta. A tracheal cannula
was inserted and bronchoalveolar lavage was conducted
[22]. A 6 ml aliquot of cold Ca+2 and Mg+2-free phosphate-
buffered saline (PBS) was used for the lavage wash. The
cold PBS was flushed into and out of the lungs two times
before the lavage fluid was collected. The bronchoalveolar
lavage (BAL) from five rats was combined and centrifuged
at 600 × g for 10 minutes using a Sorvall RC 3B Plus cen-
trifuge (Sorvall Thermo Electron Corporation, Asheville
NC). The supernatant was decanted into a new tube, while
the pellet was discarded. This acellular bronchoalveolar
lavage fluid (BALF) was then used as the vehicle for parti-
cle suspensions. The BALF was collected fresh the same
day that the particulate suspensions were made.
Particles
UFTiO2 (Aeroxide TiO2 P-25) was obtained as a gift from
Degussa Corporation (Parsippany, NJ). UFTiO2 had a pri-
mary particle size of 21 nm and was a 80/20 mixture of
anatase/rutile. FTiO2 (titanium (IV) oxide, #224227) was
purchased from Sigma-Aldrich (St. Louis, MO). FTiO2had
a primary particle size of 1 μm and was 100% rutile.
Suspension of UFTiO2 and FTiO2 in rat BALF
Ultrafine titanium dioxide (UFTiO2) and fine titanium
dioxide (FTiO2) particles were sieved using a Retsch AS
200 Sieve (Retsch GmbH, Haann, Germany) through 1.18Particle and Fibre Toxicology 2008, 5:17 http://www.particleandfibretoxicology.com/content/5/1/17
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mm, 250 μm, and 45 μm mesh screens. Particles were
weighed and suspended in rat BALF to obtain the desired
concentration. Once the particles were added to the BALF,
the suspensions were pulse sonicated with 5 individual
pulses at a duty cycle setting of 10% and an output setting
of 1 with a Branson 450 Sonifier probe sonicator (Bran-
son Ultrasonics Corporation, Danbury CT.). This method
has been reported previously by our laboratory to result in
well dispersed suspensions as determined by light and
electron microscopy [14]. Dynamic light scattering of
UFTiO2 suspended in a BALF model medium indicated
that ultrafine particles had a diameter of 204 ± 18 nm
[16].
In vivo exposures
To receive their respective dose of particles, each rat was
anesthetized with an intraperitoneal (i.p.) injection of
methohexital sodium (30–40 mg/kg body weight; Mon-
arch Pharmaceuticals, Bristol, TN). Each animal was then
instilled via intratracheal instillation (IT) using a 20-gauge
4-inch ball tipped animal feeding needle [22]. Each ani-
mal was instilled with 0.3 ml of UFTiO2 or FTiO2 sus-
pended in BALF. BALF (0.3 ml) was instilled as the
control. Results from our laboratory indicate that instilla-
tion of BALF does not cause lung inflammation [14]. In
addition, suspension of quartz in BALF did not alter its
inflammatory potency [14].
Bronchoalveolar lavage and cell differentials
At 24-hours, 7 days, and 42 days post-IT, the animals were
euthanized with an i.p. injection of sodium pentobarbital
(>100 mg/kg body weight) and exsanguinated by cutting
the descending aorta. A tracheal cannula was inserted and
bronchoalveolar lavage (BAL) was conducted [22]. A 6 ml
aliquot of cold Ca+2 and Mg+2 free PBS was used for the
first lavage wash. The cold PBS was flushed into and out
of the lungs two times before the lavage fluid was col-
lected. After the first lavage wash was collected and stored
separately, the BAL continued with 8 ml aliquots of cold
Ca+2 and Mg+2-free PBS until an additional 80 ml of bron-
choalveolar lavage was collected. The BAL was then centri-
fuged at 600 × g for 10 minutes using a Sorvall RC 3B Plus
centrifuge (Sorvall Thermo Electron Corporation, Ashe-
ville NC). After centrifugation, the supernatant from the
first lavage wash was decanted into a clean conical vial
and was stored on ice to be used for lung damage/cytotox-
icity analysis. The remaining supernate from the lavages
was discarded, and the cells remaining were washed with
cold Ca+2 and Mg+2-free PBS and spun again at 600 × g for
10 minutes. After this, the supernatant was discarded and
the cells were resuspended in 1 ml of HEPES-buffered
medium. Using these lavage samples, polymorphonuclear
neutrophil (PMN) and alveolar macrophage (AM) counts
were determined to assess inflammation. The number of
AM and PMN was determined according to their unique
cell diameters, using an electronic cell counter equipped
with a cell sizing attachment (Beckman Coulter Multisizer
3 Counter, Hialeah, FL).
BAL fluid lactate dehydrogenase activity and albumin 
concentration
The degree of cytotoxicity induced by the instilled parti-
cles was determined by lactate dehydrogenase (LDH)
activity in the BALF. LDH activity was measured using a
Roche COBAS MIRA Plus chemical analyzer (Roche Diag-
nostic Systems Inc., Branchburg, NJ) as described previ-
ously by our laboratory [22]. Albumin concentrations in
BALF were assessed to examine if instilled particle expo-
sures had compromised the integrity of the alveolar air/
blood barrier. Albumin concentrations were also meas-
ured using a Cobas Fara II Analyzer (Roche Diagonostic
Systems, Montclair, NJ) as previously described by our
laboratory [22].
Mediator measurements in bronchoalveolar lavage fluid
The presence of inflammatory mediators in the BALF was
analyzed by enzyme-linked immunosorbent assay
(ELISA). The levels of mediators present were measured
using commercially available ELISA kits (BioSource Inter-
national Inc., Camarillo, CA). Three mediators were quan-
tified: tumor necrosis factor-α (TNF-α), interleukin (IL)-β,
and macrophage-inflammatory protein-2 (MIP-2).
Zymosan-stimulated and NO-dependent alveolar 
macrophage chemiluminescence
Reactive oxygen species production was determined by
measuring AM chemiluminescence. According to Van
Dyke et al. [23], only AM will generate reactive oxygen
species in response to unopsonized zymosan in the
chemiluminecence assay procedure. The AM chemilumi-
nescence assay was conducted in the same manner as pre-
viously described by our laboratory [22]. Briefly, resting
AM chemiluminescence was determined by incubating
1.0 × 106 AM/ml at 37°C for 20 minutes, followed by the
addition of 5-amino-2,3-dihydro-1,4, phthalazinedione
(luminol) to a final concentration of 0.08 μg/ml. This was
then followed by the measurement of chemiluminescence
generated over 15 minutes.
Zymosan-stimulated chemiluminescence was determined
by adding unopsonized zymosan (2 mg/ml) to the AM
samples immediately prior to measurement of chemilu-
minescence. NO-dependent chemiluminescence was
determined by adding the unopsonized zymosan as well
as N-nitro-L-arginine methyl ester HCL (L-NAME) to the
AM samples immediately prior to measurement of chemi-
luminescence. Zymosan-stimulated (zymosan – rest) and
NO-dependent (zymosan – zymosan with L-NAME)
chemiluminescence were both measured using a Berthold
automated luminometer (Berthold Autolumat LB 953,Particle and Fibre Toxicology 2008, 5:17 http://www.particleandfibretoxicology.com/content/5/1/17
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EG&G, Gaithersburg, MD) at 390–620 nm for 15 min-
utes.
Tissue collection and analysis for titanium dioxide burden 
analysis
Immediately after the 7 and 42- day exposure time peri-
ods, rats were euthanized with an i.p. injection of sodium
pentobarbital (>100 mg/kg body weight). The left and
right lungs as well as the tracheobronchial (TBL) and
thymic (TLN) lymph nodes were removed for titanium
dioxide burden analysis. After removal, the lungs and
lymph nodes were weighed and then frozen at -80°C. The
lungs and lymph nodes were then lyophilized. The
lyophilized samples were sent to Bureau Veritas North
America, Inc. (Novi, MI) for TiO2 metal analysis.
Histopathology
Immediately after the 7 and 42 days exposure, rats were
euthanized with i.p. injection of sodium pentobarbital (>
100 mg/kg body weight). The lungs were removed and
infused to 25 cm H2O with 10% buffered neutral forma-
lin. Paraffin-embedded histologic sections were stained
with hematoxylin and eosin (H&E) or Masson's trichrome
for light microscopic examination by a board-certified vet-
erinary pathologist.
Statistics
Statistical differences between control groups and treat-
ment groups for the in vivo experiments examining the
toxicity of titanium dioxide were determined using an
analysis of variance (ANOVA). Individual means were
compared using the Student-Newman-Keuls Method
multiple comparison procedure with an overall signifi-
cance level of p= 0.05. A linear regression curve analysis
with a 95% confidence interval was also conducted on the
surface area data for each pulmonary parameter meas-
ured.
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